BMEA241220C15000
- 0.51
- +0.11+27.50%
Biomea Fusion Newsroom
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $41
Scotiabank Sticks to Their Buy Rating for Biomea Fusion (BMEA)
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $40
Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Biomea Fusion Analyst Ratings
D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $128 Price Target
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $41
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $19 to $60
Biomea Fusion Is Maintained at Equal-Weight by Barclays
Biomea Fusion Analyst Ratings
EF Hutton Maintains Buy on Biomea Fusion, Maintains $128 Price Target
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $40
Biomea Fusion Analyst Ratings
Biomea Fusion Initiated With a Buy at EF Hutton
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $10
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Raises Target Price to $41
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $10 to $60
Biomea Fusion Price Target Raised to $41.00/Share From $21.00 by Scotiabank
Biomea Upgraded by Analysts After FDA Lifts Clinical Hold
Biomea Fusion Is Maintained at Equal-Weight by Barclays